A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in
combination with BGB-3245 in adult participants with histologically confirmed, advanced
(American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid
cancer that is refractory to or has progressed during or after at least 1 line of appropriate
prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate
targeted therapy, or for which there is no treatment available, or prior standard of care
therapy was not tolerated.